Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis (EndoSorb)
An Open-label Randomized Controlled Experimental Endotoxemia Study on the Effects of the Cytokine-adsorber CytoSorb on the Development of Immunoparalysis in Humans
Sponsor: CytoSorbents Europe GmbH
Listed as NCT04643639, this PHASE3 trial focuses on Blood Purification and Hemoperfusion and remains completed. Sponsored by CytoSorbents Europe GmbH, it has been updated 7 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Mar 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Apr 2021 — Mar 2022 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CytoSorbents Europe GmbH
- Radboud University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .